IMNM Q2 2023 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

-$1M-34.1% margin

Operating Income

-$6M-135.4% margin

Net Income

-$6M-130.4% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+80.3%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$41M

Total Liabilities

$32M

Stockholders' Equity

$9M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	-$1M	$0	—
Operating Income	-$6M	-$9M	+35.3%
Net Income	-$6M	-$9M	+37.7%